Publication:
Maternal Serum Screening for Prenatal Diagnosis of Some Fetal Genetic Disorders

Simple item page
dc.authorscopusid35607779500
dc.authorscopusid6604044714
dc.contributor.authorMalatyalioǧlu, E.
dc.contributor.authorYanik, F.
dc.date.accessioned2025-12-11T02:00:05Z
dc.date.issued1999
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Malatyalioǧlu] Erdal, Tip Fakultesi, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Yanik] Filiz Fatma Bilgin, Tip Fakultesi, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractBased on elevated MSAFP levels, 85% to 90% of NTDs can be detected. Using a combination of the three parameters, MSAFP, hCG and UE3, 55% to 60% of fetal Down's syndrome can be detected. Future strategies for Down's syndrome screening may include the use of new markers such as dimeric inhibin-A and urinary β-core fragment of hCG, as well as first-trimester screening, particularly with PAPP-A and free β-hCG.en_US
dc.identifier.endpage85en_US
dc.identifier.issn1300-2996
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-0032914724
dc.identifier.scopusqualityN/A
dc.identifier.startpage76en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/47532
dc.identifier.volume16en_US
dc.identifier.wosqualityN/A
dc.language.isotren_US
dc.relation.ispartofOndokuz Mayis Universitesi Tip Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectΑ-Fetoproteinen_US
dc.subjectDown'S Syndromeen_US
dc.subjectHuman Chorionic Gonadotropinen_US
dc.subjectNeural Tube Defectsen_US
dc.subjectTriple Markeren_US
dc.subjectUnconjugated Estriolen_US
dc.titleMaternal Serum Screening for Prenatal Diagnosis of Some Fetal Genetic Disordersen_US
dc.title.alternativeBazı Fetal Genetik Hastalıkların Prenatal Tanısında Maternal Serum Taramasıen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu